Andre Milani Reis

Andre Milani Reis

Auto-generated profile, based on publicly available information

Andre Milani Reis

State University of Campinas, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2025 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
ARAndre Milani Reis
Andre Milani Reis
MMMaria Meritxell Roca Mora
Maria Meritxell Roca Mora
PBPedro Bicudo Bregion
Pedro Bicudo Bregion
LKLucas Kreutz-Rodrigues
Lucas Kreutz-Rodrigues
SCSteven Camp
Steven Camp
BSBasel A Sharaf
Basel A Sharaf
Buttock augmentation has become one of the most sought-after cosmetic procedures, but concerns over fat embolism-related fatalities have raised significant safety issues. Guidelines emphasize that fat grafting should remain in the subcutaneous layer, avoiding intramuscular injection. This systematic review and meta-analysis assess the efficacy and safety of ultrasound-guided gluteal fat grafting. A systematic search of PubMed, Cochrane Central Register of Controlled Trials, and Embase was conducted until July 2024, analyzing patient satisfaction, complication rates, mortality, fat embolism, fat necrosis, infection, and seroma. Statistical analyses, including the Freeman–Tukey Double Arcsine Transformation, were performed using R version 4.1.2. Four studies with a total of 6235 female patients (mean age 34 years, BMI 30.1 kg/m2) met the inclusion criteria. The pooled analysis showed no reported mortality (0.00 per 100, 95% CI, 0.00-0.00) or fat embolism (0.00 per 100, 95% CI, 0.00-0.00). Minor complications occurred at a rate of 6.32 per 100 (95% CI, 3.23-10.27), with seroma at 2.94 per 100 (95% CI, 0.97-5.75), infection at 0.23 per 100 (95% CI, 0.00-0.96), and fat necrosis at 0.09 per 100 (95% CI, 0.01-0.23; I2 = 0). The findings indicate that ultrasound-guided gluteal fat grafting is associated with low complication rates and no reported serious adverse events, such as death or fat embolism, reinforcing its role as a safer technique for buttock augmentation. Level of Evidence: 3 (Therapeutic)

1 January 2026 in Hepatology Forum
Verified
Journal Article
Open access
ACAna Carolina Covre Coan
Ana Carolina Covre Coan
VJVanio Antunes Do Livramento Junior
Vanio Antunes Do Livramento Junior
APAlonzo Armani Prata
Alonzo Armani Prata
NMNatália Junkes Milioli
Natália Junkes Milioli
TCTulio L Correa
Tulio L Correa
MFMatheus Vanzin Fernandes
Matheus Vanzin Fernandes
Background and Aim: Hepatic encephalopathy (HE) is a complication of cirrhosis and one of the most important manifestations of this disease. Intravenous albumin may have the potential to mitigate oxidative stress injury inherent to the pathogenesis of HE. Our study aims to evaluate the efficacy and safety of albumin for the treatment of HE. Materials and Methods: We performed a systematic review and meta-analysis using the PubMed, Embase, and Cochrane databases. We searched for randomized controlled trials (RCTs) comparing albumin to placebo in patients with HE and decompensated cirrhosis. The outcomes were mortality and clinical improvement of HE. The odds ratio (OR) was used for binary outcomes and the mean difference (MD) for continuous outcomes with their respective 95% confidence interval (CI). Heterogeneity was assessed using the Cochran Q test and I² statistics. Trial sequential analysis (TSA) was performed for all outcomes. Results: This study included four RCTs, amounting to 306 patients. There was a significant difference favoring albumin use for mortality (OR 0.44; 95% CI 0.24 to 0.79; p=0.007; I2=0%) and for HE improvement (OR 2.41; 95% CI 1.22 to 4.75, p=0.011; I2=34.9%) compared to placebo. There was no significant difference in ammonia levels (p=0.580), liver transplantation (p=0.732), and significant adverse events (AE) rate (p=0.586). TSA revealed that the pooled effect is statistically significant for mortality reduction with albumin use; however, regarding sample size, the result is not definitive. Conclusion: In patients with HE, intravenous albumin leads to HE improvement and reduced mortality, without an increase in AE rates. However, the TSA indicated that further studies are required to draw precise evidence regarding the use of albumin to reduce mortality in this population.

1 January 2026 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
ACAna Carolina Covre Coan
Ana Carolina Covre Coan
VJVanio Antunes Do Livramento Junior
Vanio Antunes Do Livramento Junior
APAlonzo Armani Prata
Alonzo Armani Prata
NMNatália Junkes Milioli
Natália Junkes Milioli
TCTulio L Correa
Tulio L Correa
MFMatheus Vanzin Fernandes
Matheus Vanzin Fernandes
Hepatology Forum (HF) is the double-blind peer-reviewed, open access, international official journal of Turkish Association for the Study of the Liver (TASL). Yearly four issues of the journal are being published (January, April, July, October). The journal’s publication language is English.